2. Search Result
Search Result
Results for "

Counteracting effects

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

2

Inhibitory Antibodies

9

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2922
    β-Amyrin

    		Amyloid-β NF-κB Neurological Disease Inflammation/Immunology
    β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound .
    β-Amyrin
  • HY-B0763
    Ibudilast
    5+ Cited Publications

    KC-404; AV-411; MN-166

    		 Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast
  • HY-111152
    ML115
    5+ Cited Publications

    		 STAT Cancer
    ML115, a molecular probe of the signal transducer, is a selective STAT3 agonist, with an EC50 of 2 nM. ML115 increases the expression of BCL3, a known STAT3-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056)-stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers .
    ML115
  • HY-100609
    4-P-PDOT
    5+ Cited Publications

    		 Melatonin Receptor Neurological Disease
    4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) .
    4-P-PDOT
  • HY-P99019
    Fremanezumab
    2 Publications Verification

    TEV-48125; LBR-101; PF-04427429; RN-307

    		 CGRP Receptor Neurological Disease Inflammation/Immunology
    Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
    Fremanezumab
  • HY-B1022
    Dimesna
    1 Publications Verification

    BNP-7787

    		 Drug Derivative Endocrinology Cancer
    Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .
    Dimesna
  • HY-W014504
    DL-Kynurenine

    		Endogenous Metabolite Metabolic Disease
    DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity .
    DL-Kynurenine
  • HY-153898
    rTRD01

    		Amyloid-β Neurological Disease
    rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .
    rTRD01
  • HY-N6977
    Ascr#3

    		Others Infection
    Ascr#3 is a type of pheromone found in the beautiful nematode, and when mixed with ascr#2, it can act as a male attractant and also induce the formation of dauer (the dormant larval stage). Ascr#3 can counteract the effects caused by male-enriched Ascr#10 .
    Ascr#3
  • HY-P0264A
    Exendin(9-39) amide acetate
    30+ Cited Publications

    Avexitide acetate

    		 GLP Receptor Metabolic Disease
    Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .
    Exendin(9-39) amide acetate
  • HY-120717
    VU6001966

    		mGluR Cytochrome P450 Neurological Disease
    VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder .
    VU6001966
  • HY-P1139
    Cortistatin-8

    PCFWKTCK

    		 GHSR Metabolic Disease
    Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .
    Cortistatin-8
  • HY-N1989
    Bacoside A

    		Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB Neurological Disease Cancer
    Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na +/K +-ATPase, Ca 2+-ATPase and Mg 2+-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .
    Bacoside A
  • HY-P11043
    GEP44

    		GLP Receptor Neuropeptide Y Receptor Arrestin Metabolic Disease
    GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
    GEP44
  • HY-165527
    S18327

    		Dopamine Receptor 5-HT Receptor Neurological Disease
    S18327 is a multi-target antipsychotic agent. S18327 exerts its efficacy by acting on multiple neurotransmitter systems in the brain, and it has antagonistic effects on dopamine receptors (particularly the D2 receptor) and 5-hydroxytryptamine 2A receptors (5-HT2A receptor). S18327 can counteract excessive dopamine activity and hypo-function of glutamate. S18327 exhibits a multi-parameter pharmacological profile that is highly similar to that of Clozapine (HY-14539). S18327 can produce the same discriminative stimulus as Clozapine, improve cognitive filtering deficits associated with schizophrenia, and display anxiolytic properties. S18327 has relatively weak affinity for histaminergic receptors and muscarinic receptors, which avoids the side effects of Clozapine .
    S18327
  • HY-121918
    RU 41656

    		Others Others
    RU 41656 partially alleviated triazolam-induced memory impairment but did not counteract the sedative effects of this agent .
    RU 41656
  • HY-B0763S1
    Ibudilast-d7

    		Isotope-Labeled Compounds Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast-d7
  • HY-B0763R
    Ibudilast (Standard)

    KC-404 (Standard); AV-411 (Standard); MN-166 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast (Standard)
  • HY-B0763S
    Ibudilast-d3

    		Isotope-Labeled Compounds Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast-d3 (KC-404-d3) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast-d3
  • HY-B0763S2
    Ibudilast-d7-1

    KC-404-d7-1; AV-411-d7-1; MN-166-d7-1

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Ibudilast-d7-1 is the deuterium labeled Ibudilast . Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast-d7-1
  • HY-W010902
    Calcium fructose diphosphate

    Dicalcium 1,6-di-O-phosphonato-L-tagatose

    		 Endogenous Metabolite ATP Synthase Metabolic Disease
    Calcium fructose diphosphate (Dicalcium 1,6-di-O-phosphonato-L-tagatose) is a crucial intermediate in the glycolysis process and is closely related to ATP synthesis. Calcium fructose diphosphate can be used to regulate calcium and phosphorus balance, protect myocardial tissue from ischemia/reperfusion injury, counteract the effects of alcohol, and serve as a safer source of phosphate in parenteral nutrition .
    Calcium fructose diphosphate
  • HY-N2922R
    β-Amyrin (Standard)

    		Reference Standards Amyloid-β Neurological Disease
    β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound .
    β-Amyrin (Standard)
  • HY-176238
    CX116

    		Apoptosis Metabolic Disease Cancer
    CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI) .
    CX116
  • HY-B1022A
    Dimesna free acid

    BNP-7787 free acid

    		 Drug Derivative Endocrinology Cancer
    Dimesna (BNP-7787) free acid, the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna free acid converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna free acid does not interfere with the antitumor activity of platinum compounds. Dimesna free acid does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna free acid counteracts Cisplatin-induced nephrotoxicity. Dimesna free acid exerts selective protective effects on the kidneys. Dimesna free acid can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .
    Dimesna free acid
  • HY-N0272R
    Eleutheroside E (Standard)

    		Reference Standards Others Inflammation/Immunology
    Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis .
    Eleutheroside E (Standard)
  • HY-W014504S1
    DL-Kynurenine-d7

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    DL-Kynurenine-d7 is the deuterium labeled DL-Kynurenine. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine-d7
  • HY-W014504R
    DL-Kynurenine (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    DL-Kynurenine (Standard) is the analytical standard of DL-Kynurenine. This product is intended for research and analytical applications. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine (Standard)
  • HY-100609R
    4-P-PDOT (Standard)

    		Reference Standards Melatonin Receptor Neurological Disease
    4-P-PDOT (Standard) is the analytical standard of 4-P-PDOT. This product is intended for research and analytical applications. 4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) .
    4-P-PDOT (Standard)
  • HY-179142
    COX-2-IN-60

    		COX TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .
    COX-2-IN-60
  • HY-114401
    3,4-Dimethyl-5-pentyl-2-furannonanoic acid

    		Drug Derivative Others
    3,4-Dimethyl-5-pentyl-2-furannonanoic acid is a furan fatty acid with a pentyl side chain. It is produced from Linoleic acid (HY-N0729). 3,4-Dimethyl-5-pentyl-2-furannonanoic acid counteracts the negative effects associated with intracellular oxidative stress .
    3,4-Dimethyl-5-pentyl-2-furannonanoic acid
  • HY-P992153
    Serrumab

    		Interleukin Related Inflammation/Immunology
    Serrumab is a human monoclonal antibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .
    Serrumab
  • HY-N6977R
    Ascr#3 (Standard)

    		Others Reference Standards Infection
    Ascr#3 (Standard) is the analytical standard of Ascr#3 (HY-N6977). This product is intended for research and analytical applications. Ascr#3 is a type of pheromone found in the beautiful nematode, and when mixed with ascr#2, it can act as a male attractant and also induce the formation of dauer (the dormant larval stage). Ascr#3 can counteract the effects caused by male-enriched Ascr#10 .
    Ascr#3 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: